Published in Vaccine Weekly, April 29th, 1996
Current chemotherapeutics are capable of inducing remission in 60 to 80 percent of AML patients. Unfortunately, long-term survival is usually only achieved in 25 to 30 percent of these patients.
Motivated by the need for new therapeutic modalities for AML, and encouraged by the recent discoveries in tumor immunology, Kyriaki Dunussi-Joannopoulos et al. tested the antitumor effects of a cancer vaccine specific against AML in a murine model ("Irradiated B7-1 Transduced Primary Acute...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.